Liuchang Tan

Dr. Liuchang Tan


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
DLDan Luo
Dan Luo
HTHui Tang
Hui Tang
LTLiuchang Tan
Liuchang Tan
LZLong Zhang
Long Zhang
LWLei Wang
Lei Wang
JWJinjin Wu
Jinjin Wu
Aberrant long noncoding RNAs just proximal to Xist (lncRNA JPX) expression levels have been detected in multiple tumors. However, whether JPX is involved in melanoma progression remains unclear. Our study showed that JPX expression is significantly increased in melanoma tissues and cell lines. To clarify the effect of JPX on cutaneous melanoma, we successfully generated JPX-overexpressing or JPX-knockdown A375 and A2058 cells. CCK-8, colony formation EdU, Transwell, and cell-cycle phase assays were performed, and subcutaneously implanted tumor models were used to determine the function of JPX in cutaneous melanoma. The results showed that JPX knockdown reduced the proliferation and migration of malignant melanoma cells both in vitro and in vivo. To further elucidate the molecular mechanism of JPX-induced cutaneous melanoma deterioration, we performed RNA pull-down, RNA immunoprecipitation, coimmunoprecipitation, Western blot, and RNA-sequence analyses. JPX can directly interact with YTHDF2 and impede the protection of YTHDF2 from ubiquitin-specific protease 10 (USP10), which promotes its deubiquitination. Thus, JPX decreases protein stability and promotes the degradation of YTHDF2, thereby stabilizing BMP2 mRNA and activating AKT phosphorylation. Overall, our study revealed a novel effect of JPX on YTHDF2 ubiquitination, suggesting the possibility of blocking the JPX/USP10/YTHDF2/BMP2 axis as a prospective therapeutic approach for cutaneous melanoma. Implications: This study highlights the ubiquitination effect of USP10 and JPX on YTHDF2 in cutaneous melanoma, and proposes that the JPX/USP10/YTHDF2/BMP2 axis may be a prospective therapeutic target for cutaneous melanoma.

28 February 2025 in Pathology - Research and Practice
Verified
Journal Article
Closed access
YLYing Liu
Ying Liu
DLDan Luo
Dan Luo
YLYuanGang Lu
YuanGang Lu
LTLiuchang Tan
Liuchang Tan

20 December 2021 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
ZHZhiqiang He
Zhiqiang He
SLShun Lei
Shun Lei
FLFucheng Liang
Fucheng Liang
LTLiuchang Tan
Liuchang Tan
WZWeinan Zhang
Weinan Zhang
YLYuanGang Lu
YuanGang Lu
Albendazole (ABZ) is an effective broad-spectrum anthelmintic agent that has been widely used for humans and animals. Previous studies have reported that ABZ exhibits antitumor effects against melanoma and other different cancer types; however, it is unknown whether ABZ exerts the inhibitory effect against melanoma metastasis. In this study, we aimed to investigate the inhibitory effect of ABZ on melanoma cells. Through in vitro studies, we discovered that low-dose ABZ treatment significantly inhibited the migration and invasion, but not the proliferation, of A375 and B16-F10 cells in a dose-dependent manner. Further analysis revealed that ABZ treatment reduced the expression level of snail family transcriptional repressor 1 (Snail) in the cytoplasm and nucleus by decreasing the levels of phosphorylated AKT (pAKT) Ser473/GSK-3β (pGSK-3β) Ser9 and increasing pGSK-3β/Tyr216, resulting in a significant upregulation of E-cadherin and downregulation of N-cadherin and ultimately reversing the epithelial-mesenchymal transition (EMT) process of melanoma cells. In contrast, the continuous activation of AKT via transfected plasmids elevated the protein levels of pAKT Ser473/pGSK-3β Ser9 and Snail and antagonized the inhibitory action of ABZ. We also confirmed that ABZ treatment effectively inhibited the lung metastasis of melanoma in nude mice in vivo. Subsequent immunohistochemical analysis verified the decreased pAKT Ser473/pGSK-3β Ser9 and increased pGSK-3β/Tyr216 levels in ABZ-treated subcutaneous tumors. Therefore, our findings demonstrate that ABZ treatment can suppress the EMT progress of melanoma by increasing the pGSK-3β/Tyr216-mediated degradation of Snail, which may be used as a potential treatment strategy for metastatic melanoma.

1 September 2022 in Research Square
Verified
Preprint
Open access
PDF file
LTLiuchang Tan
Liuchang Tan
YLYuanGang Lu
YuanGang Lu
IntroductionE2F is a group of genes that encodes a family of transcription factors in higher eukaryotes. Although emerging evidence indicates that E2Fs are implicated in various cancer types, the diverse expression patterns and prognostic values of E2F transcription factors in SKCM have yet to be elucidated. The purpose of this study was to enhance our knowledge concerning the role of E2Fs in SKCM patients. MethodsGEPIA, The Human Protein Atlas, TIMER, cBioPortal, GeneMANIA, DAVID 6.8 and KEGG PATHWAY Database were utilized in this study.ResultsWe observed a statistically significant increased messenger RNA (mRNA) expression in E2F1/3/5/7 compared with matched normal tissues. A significant correlation was observed between the expression of E2F7/8 and the pathological stage of SKCM patients. In addition, survival analysis revealed that SKCM patients with low transcriptional levels of E2F1/2/3/6 were associated with a significantly better prognosis. Moreover, immune infiltrations analysis showed that transcriptional levels and somatic copy number alterations (SCNA) in E2F family were significantly correlated with several immune cell recruitments, including B cells, CD8+ T cells, CD4+ T cells, neutrophils, macrophages, and dendritic cells. The function of differentially expressed E2Fs and their neighboring genes were mainly linked to P53 signaling pathway, cell cycle, and oocyte meiosis. ConclusionsTaken together, our results may provide novel strategies for the selection of prognostic biomarkers and immunotherapeutic targets in SKCM patients.

3 September 2025 in Journal of Cancer Education
Verified
Journal Article
Closed access
PDF file
JLJinran Li
Jinran Li
LTLiuchang Tan
Liuchang Tan

15 August 2024 in Journal of Craniofacial Surgery
Verified
Journal Article
Open access
YLYing Liu
Ying Liu
BHBing Han
Bing Han
LTLiuchang Tan
Liuchang Tan
DJDongshuo Ji
Dongshuo Ji
XCXiaofang Chen
Xiaofang Chen
Purpose: The pathophysiology of keloid remains unclear. Exploring the immune heterogeneity and new biomarkers of keloids can help design new therapeutic targets for keloid treatments and prevention. Methods: The authors performed single-cell RNA sequencing analysis and bulk data differential gene expression analysis of public datasets(GSE92566 and GSE163973). They used Gene Ontology (GO), Gene Set Enrichment Analysis (GSEA), and immune infiltration analysis to identify the function of the differential expressed genes. Besides, the authors performed qt-PCR on keloid tissue and adjacent normal tissues from 3 patients for further verification. Results: M2 macrophage increased in keloid samples than M1 macrophage. The authors identified 2 potential novel biomarkers of keloid, IGF1 and CXCR4, which could inhibit M1 macrophage polarization. The potential mechanism could be inhibiting immune responses and anti-inflammatory activities through INF signaling and E2F targeting. The differential expression of the 2 genes was verified by clinical samples. Conclusions: The authors identified 2 immune signaling molecules associated with keloid formation (IGF1 and CXCR4) and analyzed their potential pathogenic mechanisms.